Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide imaging and efficacy study in chemotherapy-naive castration-resistant prostate cancer
2014-001161-27Phase 4Active
- Sponsor
- European Uro-Oncology Group
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enzalutamide in castration-resistant prostate cancer (CRPC) and prostate cancer (PCa), sponsored by European Uro-Oncology Group. Primary endpoints: Progression-free survival at 6 months and Progression-free survival at 12 months. Started Apr 2015; status: active.
02
Drugs
enzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2014-001161-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001161-27.